Megan Melody, Clinical Director of Cellular Therapy at Tampa General Hospital, shared on LinkedIn:
“Having a wonderful time at the International Symposium on Hodgkin Lymphoma in Cologne, Germany, sharing the initial findings from our study,
‘NU 23H06: A Phase II trial of six doses of pembrolizumab monotherapy prior to limited chemotherapy as front-line therapy for patients with classical Hodgkin lymphoma.’
Great science and great company!”
Other articles about Lymphoma on OncoDaily.